Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs

J. K. Overbeek; R. ter Heine; H. M.W. Verheul; E. Chatelut; M. A. Rudek; H. Gurney; R. Plummer; D. C. Gilbert; T. Buclin; D. M. Burger; H. J. Bloemendal; N. P. van Erp

doi:10.1016/j.esmoop.2022.100749

Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs

J. K. Overbeek, R. ter Heine, H. M.W. Verheul, E. Chatelut, M. A. Rudek, H. Gurney, R. Plummer, D. C. Gilbert, T. Buclin, D. M. Burger, H. J. Bloemendal, N. P. van Erp^*

^*Corresponding author for this work

Medical Oncology

Research output: Contribution to journal › Editorial › Academic › peer-review

6 Citations (Scopus)

33 Downloads (Pure)

Original language	English
Article number	100749
Journal	ESMO Open
Volume	8
Issue number	1
DOIs	https://doi.org/10.1016/j.esmoop.2022.100749
Publication status	Published - Feb 2023

Bibliographical note

Funding Information:
This work was supported by ZonMw , The Netherlands Organization for Health Research and Development, as part of the Goed Gebruik Geneesmiddelen program [grant 10140021910005 ]. MAR was supported by NCI grants UM1CA186691 , U24CA247648 , and P30CA006973 .

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.esmoop.2022.100749Licence: CC BY-NC-ND

PIIS2059702922003830Final published version, 613 KBLicence: CC BY-NC-ND

Cite this

Overbeek, J. K., Heine, R. T., Verheul, H. M. W., Chatelut, E., Rudek, M. A., Gurney, H., Plummer, R., Gilbert, D. C., Buclin, T., Burger, D. M., Bloemendal, H. J., & van Erp, N. P. (2023). Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs. ESMO Open, 8(1), Article 100749. https://doi.org/10.1016/j.esmoop.2022.100749

@article{49e375679f1442eb9cf7a212922ec887,

title = "Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs",

author = "Overbeek, {J. K.} and Heine, {R. ter} and Verheul, {H. M.W.} and E. Chatelut and Rudek, {M. A.} and H. Gurney and R. Plummer and Gilbert, {D. C.} and T. Buclin and Burger, {D. M.} and Bloemendal, {H. J.} and {van Erp}, {N. P.}",

note = "Funding Information: This work was supported by ZonMw , The Netherlands Organization for Health Research and Development, as part of the Goed Gebruik Geneesmiddelen program [grant 10140021910005 ]. MAR was supported by NCI grants UM1CA186691 , U24CA247648 , and P30CA006973 . ",

year = "2023",

month = feb,

doi = "10.1016/j.esmoop.2022.100749",

language = "English",

volume = "8",

journal = "ESMO Open",

issn = "2059-7029",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Off-label, but on target

T2 - the evidence needed to implement alternative dosing regimens of anticancer drugs

AU - Overbeek, J. K.

AU - Heine, R. ter

AU - Verheul, H. M.W.

AU - Chatelut, E.

AU - Rudek, M. A.

AU - Gurney, H.

AU - Plummer, R.

AU - Gilbert, D. C.

AU - Buclin, T.

AU - Burger, D. M.

AU - Bloemendal, H. J.

AU - van Erp, N. P.

N1 - Funding Information: This work was supported by ZonMw , The Netherlands Organization for Health Research and Development, as part of the Goed Gebruik Geneesmiddelen program [grant 10140021910005 ]. MAR was supported by NCI grants UM1CA186691 , U24CA247648 , and P30CA006973 .

PY - 2023/2

Y1 - 2023/2

UR - http://www.scopus.com/inward/record.url?scp=85146039991&partnerID=8YFLogxK

U2 - 10.1016/j.esmoop.2022.100749

DO - 10.1016/j.esmoop.2022.100749

M3 - Editorial

C2 - 36603522

AN - SCOPUS:85146039991

SN - 2059-7029

VL - 8

JO - ESMO Open

JF - ESMO Open

IS - 1

M1 - 100749

ER -

Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs

Bibliographical note

UN SDGs

Access to Document

Other files and links

Cite this